本帖最后由 老马 于 2013-3-13 13:43 编辑 ' G4 S4 N9 }+ d6 N* h" |( {
" W ?+ g2 H* }; G+ e4 b
健择（吉西他滨）+顺铂+阿瓦斯汀# w5 W, E8 y( z7 k' e% m
Gemzar +Cisplatin + Avastin/ p i" \4 G" {& D& B! Q( h
http://annonc.oxfordjournals.org/content/21/9/1804.full: _2 Y g: y( p t' j) f" I' B
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ; ]4 x: W. c! P
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 6 @' f- H- ]- E) M. t& O
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 \2 K$ \4 Z& `" f+ Z4 o) N6 g% Q
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 644)
% {! F& ]6 G, a% m7 I华为网盘附件：
. u5 o9 m) G2 S【华为网盘】ava.JPG
& g' {: \1 c1 G5 N6 ?1 B& G0 }4 { |
显身卡
